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BACKGROUND: No polymorphisms affecting serum FSH levels have been described in the human FSHB gene. We
have identiﬁed a potential regulatory single nucleotide polymorphism (SNP, rs10835638; G/T) 211 bp upstream from
the FSHB mRNA transcription start-site, located within a highly conserved region among placental mammals. We
aimed to determine the correlation of carrier status of rs10835638 alternative alleles with serum FSH level in men,
and testicular and hormonal parameters. METHODS: A quantitative genetic association study using a cohort of
healthy men (n 5 554; age 19.2+ + + + +1.7 years) visiting the Centre of Andrology, Tartu University Hospital, Estonia.
RESULTS: Rs10835638 (allele frequencies: G 87.6%, T 12.4%) was signiﬁcantly associated with serum FSH level
(analysis of variance: F 5 13.0, P 5 0.0016, df 5 1; regression testing for a linear trend: P 5 0.0003). Subjects
with the GG genotype exhibited higher FSH levels (3.37+ + + + +1.79 IU/l, n 5 423) compared with heterozygotes
(2.84+ + + + +1.54 IU/l, n 5 125) (P 5 0.0005), the group of T-allele carriers (GT1TT, 2.78+ + + + +1.51 IU/l, n 5 131)
(P 5 0.0005) and TT-homozygotes (2.02+ + + + +0.81 IU/L, n 5 6) (P 5 0.031). Rs10835638 was also associated with signiﬁ-
cant (P<0.05) reduction in free testosterone index and testes volume, but increased semen volume, sex hormone-
binding globulin, serum testosterone and estradiol. LH and inhibin-B levels did not differ signiﬁcantly between
groups. CONCLUSIONS: The identiﬁcation of a regulatory SNP in FSHB promoter paves the way to study the
effect of constitutively low FSH on male health and fertility. As FSH contributes to follicular development and sex
steroid production in women, the role of this FSHB variant in female reproductive success is still to be addressed.
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Introduction
FSH is a pituitary-expressed glycoprotein hormone that regu-
lates gonadal function in both sexes in mammals (Moyle and
Campbell, 1996). In females, the role of FSH in regulating fol-
licular development and sex steroid production is clear and
well understood, and FSH is routinely used for the treatment
of female infertility (Howles, 2000; McGee and Hsueh,
2000). In contrast, the role of FSH in males in regulating testi-
cular function and spermatogenesis continues to be debated
(Moudgal and Sairam, 1998; Plant and Marshall, 2001).
Studies in transgenic animals have shown that FSH-deﬁcient
female mice are infertile and demonstrate small ovaries result-
ing from a block in folliculogenesis at the pre-antral stage;
whereas male mice lacking FSH are fertile, although with
reduction in testicular size, and sperm count and motility
(Kumar et al., 1997).
FSH is composed of an a-subunit shared with other glyco-
protein hormones and a speciﬁc b-subunit encoded by the
FSHB gene. Human FSHB (4.2 kb) spans one non-coding
and two translated exons encoding the 129-amino acid prepro-
tein (Jameson et al., 1988) (Fig. 1a). Resequencing of FSHB
(Lamminen et al., 2005; Grigorova et al., 2007) revealed extre-
mely low variation of the gene and no non-synonymous
mutations in all studied human populations. Consistently,
only eight subjects with FSHB inactivating mutations have
been described to date (Huhtaniemi, 2003; Berger et al.,
2005). Female patients (n ¼ 5) were suffering from primary
amenorrhea, disturbed pubertal development and infertility.
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but the effect of inactivating mutations on pubertal develop-
ment varied. The FSHB gene sequence has only two major var-
iants worldwide (carried by up to 96.6% of each population
sample) and exhibits a signiﬁcant deviation from neutrality
suggesting a possible effect of balancing selection (Grigorova
et al., 2007). Although transcription of FSHB is rate-limiting
for FSH production and controls most of FSH secretion
(reviewed by Miller et al., 2002), there is a shortage of data
on the transcriptional regulation of the human gene and so
far no FSHB polymorphisms altering gene expression have
been identiﬁed. In this study, we have screened evolutionary
conserved regions upstream of the human FSHB gene and
report the ﬁrst promoter variant which is signiﬁcantly associ-
ated with serum FSH levels in healthy young men.
Materials and Methods
Study group
The study has been approved by the Ethics Committee of Human
Research of the University Clinic of Tartu, Estonia (permission no.
112/3, 27 January 2003). The study was carried out at the Centre of
Andrology, Tartu University Hospital between May 2003 and June
2004, and included 578 young men who participated in a prospective
study Environment and Reproductive Health (EU 6th FP project
QLRT-2001-02911). Participation in the study was voluntary and
informed consent was obtained from all study subjects. Principles of
the study group formation have been described previously (Punab
et al., 2002). In total, 24 subjects of the cohort with either severe
genital pathologies (cryptochism n ¼ 9) or with missing data (failed
DNA extraction, n ¼ 3; missing or incomplete sperm analysis, n ¼ 9
or hormonal data, n ¼ 3) were excluded from the analyses. The ﬁnal
number of eligible study subjects was 554 [mean age 19.2+1.7
(SD) years]. All men were born and living in Estonia.
Hormone assays
Blood was drawn from the cubital vein between 8 a.m. and 10 a.m.
after overnight fasting or light morning meal. Serum was extracted
and stored at 2808C until it was sent frozen to the Department of
Growth and Reproduction in Copenhagen, Rigshospitalet, Denmark,
for analysis. Serum levels of FSH, LH and sex hormone-binding
globulin (SHBG) were determined using a time-resolved immuno-
ﬂuorometric assay (Delﬁa, Wallac, Turku, Finland). Testosterone
levels were determined using a time-resolved ﬂouroimmunoassay
(Delﬁa), estradiol (E2) by radioimmunoassay (Pantex, Santa Monica,
CA, USA) and inhibin-B by a speciﬁc two-sided enzyme immuno-
metric assay (Serotec, UK). Free testosterone index (FTI) was calcu-
lated as (testosterone/SHBG) 3 100. All hormone assessments were
done at the end of the study in order to reduce the inﬂuence of inter-
assay variations. The intra- and inter-assay coefﬁcients of variation
(CV) for measurement of both FSH and LH were 3% and 4.5%,
respectively. The intra- and inter-assay CVs for both testosterone
and SHBG were ,8% and ,5%, for E2 and inhibin-B 7.5% and
13%, and 15% and 18%, respectively.
Semen analysis
Semen samples were obtained by masturbation and ejaculated into a
sterile collection tube, in a private room near the laboratory. After
ejaculation, the semen was incubated at 378C for 30–40 min for lique-
faction. The actual period of ejaculation abstinence was calculated as
time in hours between current and previous ejaculation as reported by
the men. Semen analysis was performed according to World Health
Organization guidelines (World Health Organization, 1999). Semen
volume was estimated by weighing the collection tube with the
semen sample and subsequently subtracting the predetermined
weight of the empty tube assuming 1 g ¼ 1 ml. The motility assess-
ment was performed in duplicate and the average value was calcu-
lated. For assessment of the sperm concentration, the samples were
diluted in a solution of 0.6 mol/l NaHCO3 and 0.4% (v/v) formal-
dehyde in distilled water. The sperm concentration was assessed
using the improved Neubauer haemocytometers. Total sperm count
was calculated by multiplying semen volume by sperm concentration.
Physical examination
Physical examination for assessment of genital pathology and testicu-
lar size was performed with the man in standing position. If necessary,
pathologies were clariﬁed further with the men in supine position. The
orchidometer (made of birch wood, Pharmacia & Upjohn, Denmark)
was used for assessment of testicular size. Participants of the study
were examined by two investigators who, immediately before the
study,had passed the specialtraining for standardization of the clinical
examination. The total testicular volume is the sum of the volume of
the right and left testicles.
Figure 1: Location of rs10835638 (G/T) (a) within the human FSHB genomic region and (b) on the comparative alignment of the conserved 50
upstream sequence element shown to act as PRE in ovine Fshb promoter (Webster et al., 1995).
Black and white boxes indicate coding and non-coding exons E1–E3, respectively. The location of the rs10835638 (position 2211) and the PRE
element (from 2212 to 2197) is shown relative to transcription start-site of the human FSHB gene. The ovine PRE element (Webster et al., 1995)
is indicated on the alignment as the boxed sequence and the nucleotide G corresponding to the position of the human polymorphism G/T is high-
lighted with larger font. Ovis aries, domestic sheep; Homo sapiens, human; Macaca mulatta, rhesus monkey; Mus musculus, house mouse; Canis
lupus, dog; Dasypus novemcinctus, Nine-banded Armadillo.
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The polymorphism located at the position 2211 from FSHB mRNA
start site (rs10835638) represents a restriction fragment length poly-
morphism. Thus, genotyping of the alternative alleles (major G/
minor T) was conducted by a PCR (forward/reverse primers:
50-GGAGCCAGATCATGAAATGTT-30/ 50-GACCAATGCTAGCC
TGAAGC- 30) and restriction enzyme digestion (TatI, Fermentas,
Lithuania) approach. The uncut PCR product (364 bp) representing
the T-allele was separated from the fragments (233 and 131 bp) result-
ing from digestion of the G-allele by electrophoreses in a 2% agarose
gel with 13 Tris/Acetic acid/EDTA buffer. Allele frequencies were
estimated and conformance with Hardy–Weinberg equilibrium was
computed by an exact test (a ¼ 0.05) using Genepop software
(Version 3.4) (http://wbiomed.curtin.edu.au/genepop/).
Data analysis
Marker–Trait association tests for the association of rs10835638 with
quantitative hormonal (FSH, LH, testosterone, SHBG and inhibin-B)
andtesticular(semenandcombinedtestesvolume,andspermmotility,
concentration and count) parameters were performed using regression
testing for a linear trend of marker alleles and one-way analysis of var-
iance (ANOVA) basedon marker genotypes.Analysis was adjusted by
age and BMI (all parameters), and abstinence period (only semen par-
ameters).Theassociationtestswereimplementedinstatisticalanalysis
package JMP
w 6.0.3 with Genomics module 2.0.6 (http://www.jmp.
com/software/genomics/).Statisticaldifferencesbetweenthecarriers
(TT homozygotes, n ¼ 6; or TTþGT n ¼ 131) and non-carriers (GG,
n ¼ 423) of the T-allele in age, abstinence period, BMI, hormonal
and testicular parameters were assessed by non-parametric Mann–
Whitney two-sided U-test, which compares the medians and the distri-
bution of values. The advantage of Mann–Whitney U-test is that it
allows differences in sample sizes among the compared groups. The
analysis was performed with a web-based implementation of the
Mann–Whitney U-test (http://eatworms.swmed.edu/~leon/stats/
utest.html). A P-value of ,0.05 was considered as signiﬁcant and a
P-value of ,0.1 was considered suggestive.
Results
Identiﬁcation of potential regulatory variant within the
highly conserved FSHB promoter element
The human genome single nucleotide polymorphism (SNP)
database (dbSNP—http://www.ncbi.nlm.gov) was screened
for potential gene regulatory polymorphisms assigned to evol-
utionary conserved sequence elements upstream of the FSHB
gene. The database search combined with comparative
genomic analysis resulted in the identiﬁcation of an uncharac-
terized SNP (rs10835638; G/T) 211 bp upstream from the
FSHB mRNA (Genbank reference: NM_001018080.1, GI:
66528994) transcription start-site. This SNP is located within
a region which is highly conserved among placental mammals
(Fig. 1b) and is predicted to harbor a transcription regulatory
element (UCSC Genome browser; http://genome.ucsc.edu/).
Consistently, functional studies conducted with ovine Fshb 50
ﬂanking region have shown that the conserved element
between 2212 and 2197 acts as progesterone responsive
element (PRE; Fig. 1b) capable of enhancing gene transcription
up to 9-fold (Webster et al., 1995). The conserved G nucleotide
atposition 2211wasshowntobeoneofthecriticalpositionsfor
the proper functioning of this element (Webster et al., 1995).
Quantitative association studies for rs10835638 with
hormonal and testicular parameters
The putative regulatory polymorphism rs10835638 in FSHB
promoter (Fig. 1) was genotyped for a cohort (n ¼ 554) of
young healthy Estonian men visiting the Andrology Center
of the Tartu University Clinics, Estonia over a 2-year period.
The genotyped cohort consisted of 423 major allele homozy-
gotes (GG; 76.4%), 125 heterozygotes (GT; 22.6%) and 6
minor allele homozygotes (TT; 1.1%). The frequencies for
G- and T-alleles were 87.6% and 12.4%, respectively.
Association analysis using regression testing for a linear
trend revealed a strong association of rs10835638 alleles
with serum FSH levels (P ¼ 0.0003; Table I). There is a gradi-
ent of declining FSH levels among the three subgroups of wild-
type homozygotes (GG), heterozygotes (GT) and homozygotes
for the minor allele (TT) of rs10835638 (ANOVA: F ¼ 13.0,
P ¼ 0.0016, df ¼ 1; Table I; Fig. 2). Signiﬁcantly higher
serum FSH was measured for the carriers of the GG genotype
(3.37+1.79 IU/l) compared with heterozygotes (2.84+
1.54 IU/l; Mann–Whitney U-test P ¼ 0.0005), the joint
group of T-allele carriers (GTþTT, n ¼ 131; 2.78+
1.51 IU/l, P ¼ 0.000502) and more remarkably compared
with TT homozygotes (2.02+0.81 IU/l; P ¼ 0.031).
Notably, the declining gradient of serum FSH among the
GG, GT and TT genotype carriers was correlated with the cal-
culated FTI (GG: 93.80+35.00 . GT: 86.88+30.16 . TT:
66.45+25.15; ANOVA: F ¼ 6.4, P ¼ 0.0274, df ¼ 1;
Table I, Fig. 2). The GT and TT carriers exhibit different
reasons for the lower FTI. In the case of GG versus GT, the
difference is attributable to lower total testosterone while
SHBG is the same; whereas for GG versus TT, the difference
is attributable to the increase in SHBG (Table I).
In addition to reduced FSH and FTI, the data suggested that
rs10835638 minor allele homozygosity (TT) might affect also
other markers of male reproductive function (Fig. 2, Table I).
This subgroup was characterized by signiﬁcant reduction
in combined testes volume (GG: 50.59+10.17 GT:
50.07+9.83 . TT: 39.33+12.94 ml; ANOVA: F ¼ 1.6,
P ¼ 0.0250, df ¼ 1), but signiﬁcantly increased E2 (GG:
102.84+26.00 GT: 97.55+24.81 , TT: 122.67+26.28;
ANOVA: F ¼ 1.33, P ¼ 0.0127, df ¼ 1) and semen volume
(GG: 3.4+1.6 GT: 3.43+1.57 , TT: 4.03+2.14 ml;
ANOVA: F ¼ 1.72, P ¼ 0.0625, df ¼ 1). For the TT homozy-
gotes, we also observed elevated serum LH, SHBG and BMI as
well as reductions in average sperm concentration and testos-
terone, but in ANOVA analysis these differences among sub-
groups did not reach statistical signiﬁcance (Table I, Fig. 2).
No effect was detected on serum inhibin-B level, or sperm
count and motility. We are aware that due to the low number
of subjects with TT genotype (n ¼ 6), the latter observations
relative to this group should be handled with caution until repli-
cated in a larger cohort.
Discussion
There is a growing consensus that the genetic component of
complex traits may reﬂect a different spectrum of sequence
variants than the missense and nonsense mutations that
Grigorova et al.
2162Table I. Characteristics of the study subjects grouped by rs10835638 (variant in human FSHB promoter) genotype.
GG (n ¼ 423) GT (n ¼ 127) TT (n ¼ 6) P-values of statistical analysis using
Regression
testing
a
ANOVA
a Mann–Whitney U-test
b
Mean (SD) Median (5–95) Mean (SD) Median (5–95) Mean (SD) Median (5–95) Allele effect Genotype
effect
TT versus
GG
TTþGT
versus GG
Subject characteristics
Age (years) 19.23 (1.73) 18.68 (17.24–22.78) 19.11 (1.68) 18.65 (17.18–22.57) 20.16 (2.56) 19.56 (17.88–23.43) 8.34 3 10
21 2.87 3 10
21 5.11 3 10
21 5.14 3 10
21
Abstinence
period (h)
111.1 (52.07) 94 (58–206) 124.5 (60.95) 112 (58.3–225.7) 124.67 (77.99) 97.5 (67–240.25) 1.61 3 10
22 4.76 3 10
22 7.88 3 10
21 5.92 3 10
22
Height (cm) 180.74 (6.73) 180 (170.1–192) 180.06 (6.92) 181 (168.3–191) 178.17 (9.58) 174.5 (170–191.5) 4.40 3 10
21 5.25 3 10
21 7.72 3 10
21 4.84 3 10
21
Weight (kg) 73 (11.14) 72 (60–90) 72.54 (10.65) 72 (60–90) 75.5 (11.84) 73.5 (63.75–90.25) 8.69 3 10
21 8.15 3 10
21 7.33 3 10
21 7.46 3 10
21
BMI 22.33 (3.1) 22.02 (18.81–27.44) 22.37 (3.06) 21.91 (18.57–27.58) 23.66 (1.81) 23.57 (21.82–25.99) 6.87 3 10
21 5.75 3 10
21 8.26 3 10
22 9.63 3 10
21
Hormone parameters
FSH (IU/l) 3.37 (1.79) 2.98 (1.29–6.74) 2.84 (1.54) 2.46 (1.14–5.4) 2.02 (0.81) 2.06 (1.06–2.91) 3.00 3 10
24 1.60 3 10
23 3.10 3 10
22 5.02 3 10
24
Inhibin-B
(pg/ml)
246.04 (79.44) 239 (130.2–389.6) 234.79 (79.32) 227 (115.9–368.7) 234.5 (94.35) 223 (134.3–352.0) 2.51 3 10
21 5.08 3 10
21 7.00 3 10
21 2.42 3 10
21
LH (IU/l) 4.08 (1.74) 3.81 (1.84–7.32) 4.08 (1.71) 3.85 (1.73–7.48) 4.68 (1.45) 4.88 (2.76–6.15) 8.67 3 10
21 6.84 3 10
21 2.52 3 10
21 8.31 3 10
21
Testosterone
(nmol/l)
29.62 (9.08) 28.4 (16.91–45.59) 27.55 (9.29) 25.2 (14.2–45.57) 27.9 (4.00) 29.1 (22.08–31.28) 2.83 3 10
22 7.51 3 10
22 7.54 3 10
21 1.38 3 10
22
Estradiol
(pmol/l)
102.84 (26) 99 (68–145) 97.55 (24.81) 92 (64.3–141.4) 122.67 (26.28) 115.5 (96–157.25) 2.49 3 10
21 1.27 3 10
22 5.98 3 10
22 5.02 3 10
22
SHBG
(nmol/l)
34.2 (12.78) 32 (18–55.9) 34.25 (16.46) 32 (18–51) 45.5 (13.84) 44 (30–63.75) 3.94 3 10
21 1.22 3 10
21 3.40 3 10
22 8.74 3 10
21
Free
testosterone
index
93.8 (35) 88.78 (50.36–150.48) 86.88 (30.16) 84 (45.93–139.1) 66.45 (25.15) 62.02 (44.48–102.21) 1.17 3 10
22 2.74 3 10
22 1.64 3 10
22 3.30 3 10
22
Testicular parameters
Total Testes
volume (ml)
50.59 (10.17) 50 (36–70) 50.07 (9.83) 50 (35–69.1) 39.33 (12.94) 43 (22–52.5) 2.07 3 10
21 2.50 3 10
22 3.92 3 10
22 6.24 3 10
21
Seminal parameters
Semen
volume (ml)
3.4 (1.6) 3.2 (1.2–6.3) 3.43 (1.57) 3.3 (1.2–6.04) 4.93 (2.14) 5.7 (1.88–6.73) 1.90 3 10
21 6.25 3 10
22 4.66 3 10
22 3.68 3 10
21
Sperm conc
(10
6/ml)
87.41 (77.14) 70 (7–219.9) 83.39 (83.54) 62 (10.3–225.7) 57.17 (41.98) 48.5 (13.75–109.25) 4.97 3 10
21 6.21 3 10
21 3.55 3 10
21 3.68 3 10
21
AþB
motility (%)
55.86 (13.19) 57 (32.1–75) 57.34 (11.72) 58.5 (41–76.75) 59.33 (9.33) 61 (48–69) 1.92 3 10
21 4.26 3 10
21 5.80 3 10
21 3.54 3 10
21
aRegression testing for a linear trend of marker alleles and one-way analysis of variance (ANOVA; tests for all traits df ¼ 1) for genotype–trait associations were performed with the following covariates: age and
BMI (all analysis), abstinence time (seminal parameters).
bMann–Whitney U-test (two-tailed) testing the difference between the medians and distributions of the study parameters for two subgroups.
Signiﬁcant difference has been highlighted: P , 0.1, P<0.05, P<0.001.
SHBG: sex hormone-binding globulin.
H
u
m
a
n
F
S
H
B
p
r
o
m
o
t
e
r
v
a
r
i
a
n
t
a
n
d
F
S
H
l
e
v
e
l
2
1
6
3dominate monogenetic diseases and traits. Within this spec-
trum, gene variants that alter gene expression are thought to
play an important role. Herewith we report the ﬁrst human
FSHB polymorphism (rs10835638; G/T; 2211 from mRNA
transcription start) showing signiﬁcant association with
serum FSH hormone levels in men. This variant is located in
the evolutionary conserved PRE-element 50 upstream of the
FSHB gene transcription site, a regulatory element
Figure 2: Boxblots for the distribution of (a) serum FSH, (b) free androgen index, (c) Inhibin-B, (d) LH, (e) combined testicular volume (left þ
right), (f) sperm concentration, (g) testosterone and (h) estradiol in study subjects subgrouped according to their FSHB promoter SNP rs10835638
genotype, either as GG (n ¼ 423), GT (n ¼ 125) or TT (n ¼ 6) individuals.
The boxes represent the 25th and 75th percentiles; whiskers are lines extending from each end of the box covering the extent of the data on 1.53
inter-quartile range. The median value is denoted as the line that bisects the boxes. Circles represent the outlier values. For each boxplot are shown
P-values of Marker–Parameter association analysis: one-way ANOVA and regression testing for a linear trend.
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2164demonstrated to be functionally active in controlling mamma-
lian FSHB expression (Webster et al., 1995). Compared with
the wild-type homozygotes (GG), the heterozygotes (GT) and
the homozygotes (TT) for the alternative allele had on
average 0.53 IU/l (15.7%) and 1.35 IU/l (40%) lower levels
of FSH in their bloodstream, respectively. The differential
effect of the two alleles (G, T) on FSHB gene expression is
supported by an independent data set from a large-scale
study focusing on the functional analysis of common human
promoter polymorphisms across 170 genes (Hoogendoorn
et al., 2003). Tested by the luciferase assay (Hoogendoorn
et al., 2003), the relative activity of the FSHB proximal
promoter carrying the rs10835638 T-allele was only half
(46–58%; P , 0.0005) compared with the activity of the
wild-type promoter variant with the G-allele in cell lines
JEG-3 and TE671, known to have progesterone-responsive
regulation of transcription (An et al., 2005; Yie et al., 2006).
The complex mechanism controlling transcription of the
FSHB gene is critical for proper regulation of the production
of FSH hormone (Miller et al., 2002). Most of the knowledge
about the transcriptional regulation of FSHB gene comes
from the studies of ovine (Webster et al., 1995; Strahl et al.,
1997; Huang et al., 2001) and murine Fshb promoters (Coss
et al., 2004; Lamba et al., 2006). An important role of
progesterone-responsive regulation in FSHB transcription is
further supported by the data from progesterone receptor
knockout mice showing moderately but signiﬁcantly lower
serum FSH levels compared with wild-type counterparts
(Schneider et al., 2005). There is limited experimental data
addressing the transcriptional regulation of the human FSHB
gene. Identiﬁcation of a regulatory polymorphism in human
FSHB promoter co-localizing with a previously mapped
ovine Fshb PRE element suggests that in addition to the high
conservation of the FSHB gene and its function among
mammals, physiologically relevant 50 upstream promoter
elements might also be conserved.
Among the healthy young men, the T-allele carriers of the
FSHB promoter SNP had decreased serum FSH levels and
reduction in combined testes volume, but no difference in
inhibin-B and sperm parameters compared with the wild-type
variant carriers. The smaller testes volume of the TT homo-
zygotes is concordant with the role of FSH as the stimulator of
seminiferous tubule growth during development in primates,
and subsequent determination of adult testicular size (Arslan
et al., 1993; Marshall and Plant, 1996; Phillip et al., 1998).
Consistently, the murine Fshb knockout model has small
testes and decreased Sertoli cell number (Kumar et al., 1997).
Lack of correlation between the drop of FSH levels and testes
volume in T-allele carriers and levels of serum inhibin-B is in
concordance with the suggestion that the Sertoli cell retains a
signiﬁcant capacity for activity which is independent of direct
hormonal regulation (Abel et al., 2008). The lower FTI and
the increase in semen volume and BMI as well as some serum
hormone levels for the T-allele carriers suggest additional
regulatory effects of FSH, beyond gonadal development and
function, on male hormonal balance and physiology.
In this ﬁrst report, we only studied the male phenotype
associated with the identiﬁed FSHB promoter polymorphism
as the cyclic variation of FSH in women makes it complicated
to reliably conduct a genetic association study with serum
hormone levels. Strong evidence for a functional consequence
of the FSHB promoter polymorphism, and the magnitude of its
effects, encourages us to proceed in asking whether differences
are seen in cycle-matched serum samples from women with
different genotypes. Previous studies have shown that in
women, the FSH receptor (FSHR) variants determined by
two common non-synonymous changes in exon 10 are associ-
ated with basal serum FSH level and are contributing to the
FSH sensitivities during the menstrual cycle and different
cycle lengths (reviewed by Gromoll and Simoni, 2005). In
contrast, the FSHR SNPs had no effect on serum levels of
FSH and other clinical parameters in men with either normal
or impaired spermatogenesis. The outcome of a combined
FSHB/FHSR SNP association study in men and women may
have therapeutic implications for fertility treatment.
In summary, although there is convincing evidence for
the role of FSH in Sertoli cell proliferation, its functional
signiﬁcance in spermatogenesis and the contribution to male
hormonal balance and physiology is unclear. The identiﬁcation
of a regulatory SNP (rs10835638) in FSHB promoter paves
the way to study the effect of constitutively reduced FSH
on male health and fertility. Furthermore, as FSH has a
well-understood contribution to the regulation of follicular
development and sex steroid production in women, the role
of the identiﬁed FSHB promoter variant in female reproductive
success is still to be studied.
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